GSK Cervical Cancer Vaccine Demonstrates Protection For Up To 6.4 Years, Latest details Shows

March 10th, 2008 | Category: Cancer

Cervarix(R), the cervical cancer vaccine made by GlaxoSmithKline, continues to show high levels of protection for up to 6.4 years, the latest notes shows.1 that period is the longest duration of protection reported so far for a cervical cancer vaccine.

The vaccine protects against strains of the human papillomavirus (HPV) - 16 and 18 - which amidst them history for 70% of cervical cancer.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • GSK Cervical Cancer Candidate Vaccine Cervarix(R) Demonstrates faraway-Term Protection For More Than Six Years
  • Gardasil Demonstrates Prevention Of Pre-Cancerous Cervical Lesions Due To Additional Cancer-Causing Human Papillomavirus Types
  • Cancerbackup Welcomes Cervical Cancer Vaccine, UK
  • Society Of Gynecologic Oncologists 39th Annual Meeting On Women’s Cancer To Include Sessions On HPV And Cervical Cancer
  • New Cell Sample Method Can Lead To Better Protection Against Cervical Cancer

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.